SonoMotion is a clinical-stage medical technology company focused on non-invasive, ultrasound-based treatments for kidney stones. Its two main products, Break Wave and Stone Clear, are designed to fragment and clear stones using low-pressure ultrasound while patients remain fully awake, eliminating the need for anesthesia and a surgical suite. Stone Clear secured FDA 510(k) de novo clearance in October 2024, and Break Wave has now finished enrollment in a 64-patient pivotal SOUND trial that will support an upcoming 510(k) submission. Together, the devices share a common platform aimed at offering a complete, first-line solution for stone management in office or clinic settings. Kidney stones affect roughly one in ten Americans and drive more than 750,000 procedures annually, representing a $10 billion U.S. market opportunity. Venture capital–backed SonoMotion continues to advance its regulatory and commercial roadmap, recently bolstered by non-dilutive NIH funding to reach key milestones.

Total raised

$25M

Funding rounds

3

Latest round

Grant

Latest activity

Apr 2025